Ten-ingredient plant-based formula referencing the AREDS-2 clinical trial evidence base alongside botanical extracts including Saffron, Ginkgo Biloba, and Bilberry — accompanied by a plain-language account of what published research supports and where it does not extend to this finished product
AURORA, Colo., Sept. 28, 2026 — Science Genics today released iGenics, a plant-based vision support supplement, alongside a full research disclosure identifying the clinical evidence basis for each ingredient — and explicitly stating where that evidence does not extend to healthy adults, early-stage conditions, or the finished formula. The product is manufactured in a GMP-certified U.S. facility.
The company’s research overview names the specific patient populations studied, the doses used in clinical trials, and the gaps between individual ingredient findings and the finished formula — disclosures that are uncommon in the vision supplement category.
“The AREDS-2 research is among the most rigorously conducted nutrition trials in ophthalmology — but it was conducted in people with existing intermediate or advanced macular degeneration, and the evidence does not extend to healthy adults or early-stage disease,” said Kent Blumen, Media Relations at iGenics. “We lead with that limitation because it is the one most likely to be obscured in category marketing. Consumers making purchasing decisions deserve the specific populations and conditions each study actually examined.”
What the Product Contains
iGenics is an ingestible dietary supplement delivered as daily capsules. Because it is an ingestible supplement, it is subject to the FDA’s dietary supplement regulatory framework under DSHEA. Like all dietary supplements, it has not undergone the pre-market approval process required of pharmaceutical drugs, and its specific formula has not been evaluated in published randomized controlled trials.
The formula combines ingredients across three categories: AREDS-2 derived vitamins and minerals with the most established clinical evidence base for age-related macular degeneration (Lutein, Zeaxanthin, Vitamin C, Vitamin E, Zinc, Copper); botanical extracts with published ocular research (Ginkgo Biloba, Bilberry, Saffron); and an absorption enhancer (Turmeric with BioPerine).
The product is manufactured in a GMP-certified U.S. facility using third-party tested ingredients. Users who are pregnant, nursing, taking prescription medications, or have a diagnosed eye condition should consult a physician or ophthalmologist before use.
AREDS-2 Vitamins and Minerals: The Most Clinically Studied Components
The AREDS-2 formulation — comprising Lutein (10 mg), Zeaxanthin (2 mg), Vitamin C (500 mg), Vitamin E (400 IU), Zinc (25–80 mg), and Copper (2 mg) — is the most rigorously studied combination of nutritional supplements for age-related macular degeneration (AMD) in the published literature.
The original AREDS study, a large randomized controlled trial conducted by the National Eye Institute (NEI), found that the AREDS formulation reduced the risk of progression to advanced AMD by approximately 25% over five years in participants with intermediate or advanced AMD. The follow-up AREDS-2 study, published in JAMA (Chew et al., 2013), enrolled 4,203 participants aged 50 to 85 across 82 clinical sites and found that replacing beta-carotene with Lutein and Zeaxanthin produced somewhat better outcomes in AMD progression and was safer for former smokers. Participants with the lowest dietary intake of Lutein and Zeaxanthin at baseline experienced the most pronounced benefit [1].
Three limitations apply. The AREDS-2 trials enrolled only participants with intermediate or advanced AMD — not healthy adults or those with early AMD, because AREDS data showed no benefit for those populations. The formulation reduces risk of progression in an existing condition, not prevention in those without AMD. And the trials used standardized pharmaceutical-grade doses that may differ from those in this formula. iGenics does not represent its formula as equivalent to the AREDS-2 trial formulation or as a treatment for AMD.
Ginkgo Biloba: Ocular Blood Flow Research With Mixed Clinical Findings
Ginkgo Biloba extract (GBE), particularly the standardized extract EGb 761, has been studied for its effects on ocular blood flow, antioxidant activity, and retinal microcirculation. Published research suggests GBE may influence ocular blood flow through vessel dilation, reduction of platelet aggregation, and anti-inflammatory effects.
A retrospective study (Shim et al., 2012, Yonsei University College of Medicine) evaluated 332 patients with normal tension glaucoma over approximately two years and found improvements in visual field mean deviation in both GBE and bilberry supplementation groups compared to controls, with the bilberry group also showing improved visual acuity [2]. A randomized, placebo-controlled crossover study (Wimpissinger et al., 2007, n=15) found an increase in optic nerve head blood flow following a single 240 mg dose of EGb 761, but this effect was not statistically significant compared to placebo [3]. The authors concluded that a single GBE dose does not influence ocular blood flow to a relevant degree. A 2013 Cochrane review found that some participants in GBE trials reported vision improvements, but these were not statistically significant across studies. iGenics includes Ginkgo Biloba for its antioxidant and vascular profile and does not attribute a specific clinically proven outcome to this ingredient.
Bilberry: Anthocyanin Research With Preliminary Human Evidence
Bilberry (Vaccinium myrtillus) contains anthocyanosides — antioxidant compounds studied for retinal protection and vascular effects. The Shim et al. 2012 study cited above found that bilberry anthocyanin supplementation improved visual field mean deviation in normal tension glaucoma patients over two years, with visual acuity improvements beyond those in the GBE group [2]. Laboratory research has found bilberry anthocyanins reduce retinal inflammation and angiogenesis in cell and animal models [4]. A systematic review (Canter & Ernst, 2004) found no evidence bilberry improves night visual acuity or contrast sensitivity in healthy subjects, despite widespread marketing claims for night vision benefits [5]. iGenics does not represent bilberry as a treatment for AMD, glaucoma, or any diagnosed eye condition.
Saffron: Randomized Clinical Trial Evidence in Early AMD
Saffron (Crocus sativus) and its active carotenoid compounds — crocin and crocetin — have been evaluated in randomized controlled trials in patients with early AMD, making saffron one of the more clinically studied botanical ingredients in the formula for this specific condition.
A randomized, double-blind, placebo-controlled crossover study (Falsini et al., 2010, n=25, early AMD) found significant improvement in retinal flicker sensitivity — a measure of photoreceptor function — during the saffron period (20 mg/day) compared to placebo [6]. A 14-month follow-up study in 29 early AMD patients reported improvements in clinical measures and patient-reported quality of vision [7]. A 2021 systematic review identified nine clinical trials on saffron in eye disorders and concluded that further studies are needed to confirm efficacy [8]. These findings apply specifically to patients with early AMD at 20 mg/day — a dose that may differ from the amount in this formula. iGenics does not represent saffron as a treatment for AMD.
Turmeric and BioPerine: Anti-Inflammatory Profile and Absorption Enhancement
Turmeric (Curcuma longa) contains curcumin, a polyphenol with documented anti-inflammatory and antioxidant properties in laboratory research. Human clinical evidence for curcumin in AMD or retinal conditions is limited — published studies are small and typically use high-dose enhanced-bioavailability formulations rather than standard turmeric extract. BioPerine is a standardized black pepper extract shown in pharmacokinetic studies to increase curcumin bioavailability by inhibiting its rapid metabolism [9]. This is a pharmacokinetic effect, not a direct vision benefit. iGenics includes Turmeric with BioPerine for its anti-inflammatory profile and absorption support and does not attribute a specific ocular outcome to this combination.
What Ingredient Research Does and Does Not Show
iGenics’ research overview separates three questions: what each ingredient is, what researchers have independently found about it, and what has been demonstrated for the finished formula taken as a daily oral supplement.
The AREDS-2 vitamins and minerals have the strongest clinical evidence of any ingredients in the formula — but that evidence applies to populations with intermediate or advanced AMD, not to healthy adults or those with early AMD. The botanical ingredients have published human research relevant to eye conditions, with saffron having the most rigorous controlled trial evidence specifically in early AMD. Turmeric and BioPerine are included for their anti-inflammatory and absorption profiles respectively, with limited direct human clinical evidence for ocular outcomes. The finished formula has not been evaluated in published randomized controlled trials. iGenics does not describe its product as clinically proven or represent any ingredient finding as applicable to the complete formula.
“Saffron has two randomized, placebo-controlled trials specifically in early AMD patients — that is a more rigorous evidence base than most botanical ingredients in this category carry,” Blumen added. “The honest disclosure is that neither those trials nor any other published study has evaluated this specific formula. We think stating that plainly, rather than leaving it implied, is what separates a research-backed product from a research-adjacent one.”
Safety and Suitability
iGenics is an ingestible dietary supplement. Users should be aware of the following:
- Individuals who are pregnant, nursing, taking prescription medications, or have a diagnosed medical or eye condition should consult a physician or ophthalmologist before use.
- Ginkgo Biloba may interact with anticoagulant medications including warfarin and aspirin. Patients on blood-thinning therapy should consult their physician before use.
- High-dose Zinc supplementation over extended periods may interfere with copper absorption — the iGenics formula includes Copper to address this, consistent with the AREDS-2 formulation approach.
- This supplement is not a substitute for regular eye examinations or for professionally prescribed treatment of AMD, glaucoma, diabetic retinopathy, or any other diagnosed eye condition.
- Deterioration in vision should be evaluated by a qualified ophthalmologist or optometrist. No supplement is a treatment for vision loss.
Product Format and Availability
iGenics is available to U.S. consumers through its official website, manufactured by Science Genics and distributed by ClickBank. The product is supplied as capsules for daily oral use. It is available in 1-month, 3-month, and 6-month supply packages.
About iGenics
iGenics is a plant-based dietary supplement designed to support eye health through a combination of AREDS-2 derived vitamins and minerals and botanical extracts, manufactured in a GMP-certified U.S. facility with third-party tested ingredients.
iGenics’ mission is to offer consumers a research-informed supplement for vision support — presenting what the published science supports for each ingredient, where evidence is limited to specific populations or conditions, and where the finished formula has not yet been evaluated in clinical trials.
References
[1] Chew EY, Clemons TE, SanGiovanni JP, et al. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. doi:10.1001/jama.2013.4997. PMID: 23644932.
[2] Shim SH, Kim JM, Choi CY, Kim CY, Park KH. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. Journal of Medical Food. 2012;15(9):818–823. doi:10.1089/jmf.2011.2005.
[3] Wimpissinger B, Berisha F, Garhoefer G, Polak K, Schmetterer L. Influence of Ginkgo biloba on ocular blood flow. Acta Ophthalmologica Scandinavica. 2007. (Randomized, double-masked, placebo-controlled crossover; single-dose, n=15; increase in optic nerve head blood flow not statistically significant vs. placebo.)
[4] Matsunaga N, Chikaraishi Y, Shimazawa M, et al. Vaccinium myrtillus (Bilberry) Extracts Reduce Angiogenesis In Vitro and In Vivo. Evidence-Based Complementary and Alternative Medicine. 2010;7(1):47–56.
[5] Canter PH, Ernst E. Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision — a systematic review of placebo-controlled trials. Survey of Ophthalmology. 2004;49(1):38–50. (No evidence of benefit for night vision in healthy subjects.)
[6] Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Investigative Ophthalmology & Visual Science. 2010;51(12):6118–6124. doi:10.1167/iovs.09-4995. (Randomized, double-blind, placebo-controlled crossover; n=25; early AMD population.)
[7] Piccardi M, Marangoni D, Minnella AM, et al. A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration. Evidence-Based Complementary and Alternative Medicine. 2012. doi:10.1155/2012/429124. (n=29; early AMD population.)
[8] Abbasi Habibeh N, et al. Saffron and eye disorders: a review. Current Neuropharmacology. 2021;19(5):713–740. PMC8033960. (Nine clinical trials identified; further studies needed.)
[9] Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353–356. doi:10.1055/s-2006-957450. (Pharmacokinetic effect; not a direct ocular outcome.)
Media Contact
Kent Blumen, Media Relations
iGenics | Science Genics
285 Northeast Ave, Tallmadge, OH 44278, USA
Email: support@sciencegenics.com
Phone: 1-800-390-6035
Website: visionbreakthrough.com
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Research referenced in this release concerns individual ingredients studied independently and does not constitute clinical evaluation of the complete iGenics formula or endorsement by the cited researchers, journals or institutions.
The post iGenics Reviews: Science Genics Launches Vision Support Supplement With Ingredient-by-Ingredient Research Overview appeared first on 24 Health Times.
